REG - Oxford Biomedica PLC - Board Change

Oxford BioMedicaAnnouncement

27/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230127:nRSa0326Oa&default-theme=true

RNS Number : 0326O  Oxford Biomedica PLC  27 January 2023

Board Change

Oxford, UK - 27 January 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, today
announces a change to the Group's Board of Directors.

Dr. Siyamak ("Sam") Rasty has informed the Board that he will not be standing
for re-election at the Company's AGM in June 2023. Sam joined the Board in
December 2020 and is a member of the Scientific and Technology Advisory
Committee and was a member of the Audit Committee until December 2021.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented: "It
has been a pleasure to have Dr. Sam Rasty on the Board. His extensive
experience in biopharma R&D and in building and growing successful gene
therapy companies has been a valuable asset to Oxford Biomedica. As we focus
on our innovation-led CDMO business, I would like to express my thanks for his
service to the Company, in particular his contribution to our work in
externalising our therapeutics business, which is progressing well, and wish
him well for the future."

Dr. Sam Rasty, Non-Executive Director of Oxford Biomedica added: "I am
honoured to have had the opportunity to serve on the Board of Oxford Biomedica
and assist the Company as it has grown to become a world leader in viral
vectors. I wish the team continued success in the future as Oxford Biomedica
focuses on becoming a world-class, innovation-led CDMO."

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Cole            / Angela Gray

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOANKABBCBKDDDB